Discovers and develops oral small-molecule integrin therapeutics. Focuses on treatments for autoimmune diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 58% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
Sales run at $521K a year. A small number, but proof the product has real buyers.
There is $704.3M in the vault; even if every debt were paid off, $702.0M would remain.
Over the last 12 months, company executives reported 39 buys and 28 sells. Management buying with its own money is usually read as a good sign.
A loss of $152.1M against $521K in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Sales are going backwards, not just slowing. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.